Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sirnaomics Reports 100% Complete Response for Lead siRNA Candidate

publication date: Aug 30, 2022

Sirnaomics reported that its lead product, an siRNA (small interfering RNA) therapy, produced a 100% complete response in patients with cutaneous basal cell carcinoma. Five patients received a 180μg dose of STP705 in the Phase II clinical trial of STP705. The candidate is composed of two siRNA oligonucleotides that target the expression of TGF-β1 and COX-2 mRNA, respectively. BCC is a nonmelanoma skin cancer associated with exposure to ultraviolet radiation from the sun. Sirnaomics is a Suzhou-Maryland biotech dedicated to RNAi drug development. More details....

Stock Symbol: (HK: 2257)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital